IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Immunovant, Inc.
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$27.62+0.89 (+3.33%)
Close on Oct 19, 2026
- Market cap
- $5.68B
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | -44.3% | -64.8% | |
| Return on assets | – | -41.2% | -58.3% | |
| Current ratio | – | 21.79 | 9.09 | |
| Diluted shares | – | 88M | 182M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Immunovant generated $1.29B from operations and spent $1.58M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.29B
Used
$1.58M
Capital expenditure$1.58M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
1of 6 tests passed in fiscal 2026. Some tests lack the figures they need.
- ProfitableNet income above zero-$505.61M
- Cash generatingOperating cash flow above zero-$407.31M
- Return on assets improvedROA up on the prior year-62.1% → -65.1%
- Earnings backed by cashOperating cash flow above net income-$407.31M vs -$505.61M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.16 → 9.09
- No dilutionShare count did not rise152M → 182M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –